Role of GLP-1 Receptor Agonists in Lowering ASCVD Risk in Type 2 Diabetes

Melanie J. Davies, MD


April 08, 2021

Type 2 diabetes is increasingly recognized as not only a metabolic disease but also a cardiovascular disorder. Indeed, atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality in this population.

Melanie Davies, an expert in diabetes at the University of Leicester in the United Kingdom, discusses the emerging role of GLP-1 receptor agonists (GLP-1 RAs) in the management of type 2 diabetes patients who have either established ASCVD or an increased risk for that disease.

She covers the major outcomes trials examining GLP-1 RA therapy in this patient population and the evidence for its use in reducing both major cardiovascular adverse outcomes and cardiovascular death.

Dr Davies then discusses the main theories on how GLP-1 RA therapy confers cardiovascular benefit, before outlining when it should be used in high-risk individuals.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.